Should pipeline nitrous oxide be discontinued in secondary care: A cost-benefit analysis

被引:0
|
作者
Majeed, Amer [1 ,3 ]
Awan, Amreen M. [2 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Anesthesia, Riyadh, Saudi Arabia
[2] McMaster Univ, Med Ctr, Dept Anesthesia, Hamilton, ON, Canada
[3] King Faisal Specialist Hosp & Res Ctr, MBC 72,POB 3354, Riyadh, Saudi Arabia
关键词
Greenhouse gases; hazardous waste; nitrous oxide;
D O I
10.4103/sja.sja_791_23
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Nitrous oxide (N2O) has seen a marked decline in its usage in recent years due to its adverse clinical effects. We audited the practice in our department to evaluate the N2O consumption and cost-effectiveness of its supply. Methodology: Electronic anesthesia records of all patients anesthetized in our main operating rooms in a typical month were reviewed retrospectively, and utilization of N2O was noted in addition to the patient demographics, surgical procedure, and specialty. Results: A total of 950 patients were anesthetized, and 3.1% received N2O. The annual usage was estimated to be 72,871 liters, with a leakage of 3,883,105 liters to the environment, posing a safety hazard and wasting 149,612.50 SAR. Conclusion: Notable costs and environmental benefits may be achieved by substituting a piped supply of N2O with portable E-cylinders on demand in operating rooms for rational use.
引用
收藏
页码:194 / 196
页数:3
相关论文
共 50 条
  • [21] Beware the cost-benefit analysis
    Spence, Des
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
  • [22] Incommensurability and cost-benefit analysis
    Adler, M
    [J]. UNIVERSITY OF PENNSYLVANIA LAW REVIEW, 1998, 146 (05) : 1371 - 1418
  • [23] In Defence of Cost-Benefit Analysis
    Ergas, Henry
    [J]. AGENDA-A JOURNAL OF POLICY ANALYSIS AND REFORM, 2009, 16 (03) : 31 - 40
  • [24] Cost-benefit analysis is the key
    Kelnar, CJH
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2000, 83 (02) : 176 - 177
  • [25] Humanizing Cost-Benefit Analysis
    Sunstein, Cass R.
    [J]. EUROPEAN JOURNAL OF RISK REGULATION, 2011, 2 (01) : 3 - 7
  • [26] Equity in cost-benefit analysis
    Hahn, Robert W.
    [J]. SCIENCE, 2021, 372 (6541) : 439 - 439
  • [27] Pediatric cost-benefit analysis
    Schulze-Gattermann, H
    Illg, A
    Lesinski-Schiedat, A
    Schoenermark, M
    Bertram, B
    Lenarz, T
    [J]. LARYNGO-RHINO-OTOLOGIE, 2003, 82 (05) : 322 - 329
  • [28] Cost-benefit analysis and population
    Broome, J
    [J]. JOURNAL OF LEGAL STUDIES, 2000, 29 (02): : 953 - 970
  • [29] Cost-benefit analysis: examples
    Linn, Mott
    [J]. BOTTOM LINE, 2011, 24 (01): : 68 - 72
  • [30] Liraglutide: A Cost-Benefit Analysis
    Schoeffski, O.
    Mentrup, S.
    Lund, N.
    Pfuetzner, A.
    [J]. DIABETES STOFFWECHSEL UND HERZ, 2010, 19 (03): : 177 - 184